Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate (Januvia®)

Stricklin, Sherea Monica; Stoecker, William V.; Rader, Ryan K.; Hood, Antoinette F.; Litt, Jerome Z.; Schuman, Thomas P.

doi:10.5070/d30d70k7b2

Cited by 14 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to BP, various other DPP-4 inhibitor-associated dermatoses have been described in the literature, including psoriasiform dermatitis, maculopapular rash, photodermatitis, eczematous rash, lichen planus, and even alopecia areata and mucositis. [5][6][7][8][9][10][11] Since the first case report in 2011 of DPP-4 inhibitorassociated BP, various publications have implicated DPP-4 inhibitors in the pathogenesis of BP. 12 DPP-4 inhibitors have been associated with a 3.2-fold increase in risk of developing BP, with vildagliptin and linagliptin being the most common inducing agents.…”

Section: Discussionmentioning

confidence: 99%

“…The literature on other DPP-4 inhibitor-associated cutaneous AEs remain limited to various case reports. [5][6][7][8][9][10][11] Lichen planus pemphigoides has been reported as an AE in a patient on vildagliptin, 18 while sitagliptin has been reported to cause lichen planus and psoriasiform dermatitis. 5,9 In our study, lichenoid dermatitis represented a significant portion (22.2%) of the cutaneous AEs noted, and this finding warrants further investigation.…”

Section: Discussionmentioning

confidence: 99%

“…Most of the existing literature focuses on DPP‐4 inhibitor‐associated BP, and thus ours is perhaps the first observational study characterizing other cutaneous AEs as well. In addition to BP, various other DPP‐4 inhibitor‐associated dermatoses have been described in the literature, including psoriasiform dermatitis, maculopapular rash, photodermatitis, eczematous rash, lichen planus, and even alopecia areata and mucositis 5–11 …”

Section: Discussionmentioning

confidence: 99%

“…The literature on other DPP‐4 inhibitor‐associated cutaneous AEs remain limited to various case reports 5–11 . Lichen planus pemphigoides has been reported as an AE in a patient on vildagliptin, 18 while sitagliptin has been reported to cause lichen planus and psoriasiform dermatitis 5,9 .…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Dipeptidyl peptidase‐4 inhibitor‐associated cutaneous eruptions: a retrospective observational study

Duraisamy

Jagadeesan

Eapen

et al. 2022

Clin Experimental Derm

View full text Add to dashboard Cite

Summary Background Dipeptidyl peptidase (DPP)‐4 plays a complex role in immune regulation and its inhibition can have effects on the pathogenesis of various skin diseases. Studies have shown that DPP‐4 inhibitors are associated with an increased risk of bullous pemphigoid (BP). Aim To analyse the clinical and histopathological features of cutaneous adverse events in patients on DPP‐4 inhibitors. Methods We performed a retrospective review of patients with suspected DPP‐4 inhibitor‐associated cutaneous adverse events, at a tertiary teaching hospital from 1 January 2017 to 31 December 2020. Exclusion criteria included previous history of chronic skin disease and lack of histopathological reports or follow‐up records. The clinical characteristics, latency period, Naranjo Adverse Drug Reaction Probability Scale and clinical outcomes were evaluated. Results In total, 18 patients (10 men, 8 women; mean age 68.6 years, range 38–89 years) were included. The DPP‐4 inhibitors used were teneligliptin (n = 6), vildagliptin (n = 6), sitagliptin (n = 4), linagliptin (n = 1) and saxagliptin (n = 1). The mean interval between therapy initiation and lesion onset was 8.8 months (range 1–24 months). The dermatoses noted were BP (n = 12; 66.6%), lichenoid dermatitis (n = 4; 22.2%), psoriasiform dermatitis (n = 1; 5.6%) and spongiotic dermatitis (n = 1; 5.6%). Eight patients (44.4%) had necrotic keratinocytes as one of the distinct histological features. Causality assessment using the Naranjo scale rated the causative role of DPP‐4 inhibitors as ‘possible’ in all patients. Of the 18 patients, 11 (61.1%) noted improvement in their condition following discontinuation of DPP‐4 inhibitors, with 5 having complete remission within 6 months of stopping the drug. Conclusion DPP‐4 inhibitor‐associated dermatoses are not necessarily limited to BP. It is necessary to recognize the possibility of other dermatoses in patients on DPP‐4 inhibitors as drug substitution/cessation may improve disease morbidity.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Dipeptidyl peptidase‐4 inhibitor‐associated cutaneous eruptions: a retrospective observational study

Duraisamy

Jagadeesan

Eapen

et al. 2022

Clin Experimental Derm

View full text Add to dashboard Cite

show abstract

“…Pemphigoid reactions are seen to occur most frequently, with 76 of the cases attributed to this adverse event [14]. Cutaneous reactions discussed in the literature fall into the subcategories of immunologic CADRs exanthematous (generalized skin eruption [57], maculopapular eruption [58], and DRESS syndrome [59]), blistering (pemphigoids [60][61][62][63][64][65][66][67], SJS [68], TEN [68], fixed drug eruption [69]), hypersensitivity vasculitis [68], and photosensitivity [70]…”

Section: Dpp-4 Inhibitorsmentioning

confidence: 99%

Cutaneous Reactions to Antidiabetic Agents: A Narrative Review

Boccardi

Shubrook

2022

Diabetology

View full text Add to dashboard Cite

Diabetes is a common and complex disease affecting multiple organ systems throughout the body. With a consensus in care guidelines emphasizing the importance of glycemic control in determining the disease progression, people with diabetes worldwide have been placed on medication regimens targeting glucose stability from a variety of pathophysiologic pathways. Each of these medications also possesses its own potential for adverse events. In recent years, there has been increased reports of skin reactions to diabetes medications, adding to the more widely known eruptions such as insulin-induced lipohypertrophy and contact dermatitis of subcutaneous injections. The authors searched PubMed, Google, and Embase for articles including adverse reactions to anti-hyperglycemic medications. Key words and titles searched included, “antidiabetic drugs”, “skin reactions”, “adverse drug reactions”, “allergic reactions”, “diabetes”, “metformin”, “insulin”, “DPP4 inhibitors”, “thiazolindineones”, “sulfonylureas”, “SGLT2 inhibitors”, “GLP-1 agonists”, “diabetic medication”, “injection site reactions”. As a result, a total of 59 papers are included in this review. The great majority were case reports ranging from benign fixed drug eruptions to severe cutaneous reactions that threaten patients’ lives. Increasing physician awareness of both the potential for, and presentation of, such reactions to diabetes medications can reduce hospitalizations and optimize care in an already vulnerable patient population.

show abstract

Quality of Adverse Drug Reaction (QADRA) reports: an algorithm to appraise the efficiency of spontaneous reporting systems in pharmacovigilance

et al. 2013

View full text Add to dashboard Cite

Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate (Januvia®)

Cited by 14 publications

References 0 publications

Dipeptidyl peptidase‐4 inhibitor‐associated cutaneous eruptions: a retrospective observational study

Dipeptidyl peptidase‐4 inhibitor‐associated cutaneous eruptions: a retrospective observational study

Cutaneous Reactions to Antidiabetic Agents: A Narrative Review

Quality of Adverse Drug Reaction (QADRA) reports: an algorithm to appraise the efficiency of spontaneous reporting systems in pharmacovigilance

Contact Info

Product

Resources

About